159 related articles for article (PubMed ID: 8195034)
1. The effect of low pH and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitro.
Skarsgard LD; Vinczan A; Skwarchuk MW; Chaplin DJ
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):363-7. PubMed ID: 8195034
[TBL] [Abstract][Full Text] [Related]
2. The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
Keohane A; Godden J; Stratford IJ; Adams GE
Br J Cancer; 1990 May; 61(5):722-6. PubMed ID: 2110815
[TBL] [Abstract][Full Text] [Related]
3. The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells.
Skarsgard LD; Skwarchuk MW; Vinczan A; Chaplin DJ
Br J Cancer; 1993 Oct; 68(4):681-3. PubMed ID: 8398693
[TBL] [Abstract][Full Text] [Related]
4. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay.
Stratford IJ; Stephens MA
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):973-6. PubMed ID: 2495261
[TBL] [Abstract][Full Text] [Related]
5. DNA damaging effects and voltammetric studies on the hypoxic cell toxin 3-amino-1,2,4-benzotriazine-1,4-dioxide, SR4233, as a function of pH.
Tocher JH; Virk NS; Edwards DI
Biochem Pharmacol; 1990 Sep; 40(6):1405-10. PubMed ID: 2144963
[TBL] [Abstract][Full Text] [Related]
6. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin.
Koch CJ
Cancer Res; 1993 Sep; 53(17):3992-7. PubMed ID: 8358728
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
Blumenthal RD; Taylor A; Osorio L; Ochakovskaya R; Raleigh JA; Papadopoulou M; Bloomer WD; Goldenberg DM
Int J Cancer; 2001 Nov; 94(4):564-71. PubMed ID: 11745445
[TBL] [Abstract][Full Text] [Related]
8. Assessment of micronucleus induction in SCCVII cells treated with bioreductive agents, WIN 59075 (SR 4233) and mitomycin C, under aerobic and hypoxic conditions.
Shibata T; Shibamoto Y; Sasai K; Oya N; Takagi T; Murata R; Abe M
Mutat Res; 1995 Apr; 342(3-4):171-7. PubMed ID: 7715618
[TBL] [Abstract][Full Text] [Related]
9. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
Saunders MP; Patterson AV; Chinje EC; Harris AL; Stratford IJ
Br J Cancer; 2000 Feb; 82(3):651-6. PubMed ID: 10682679
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
Patterson AV; Saunders MP; Chinje EC; Talbot DC; Harris AL; Strafford IJ
Br J Cancer; 1997; 76(10):1338-47. PubMed ID: 9374381
[TBL] [Abstract][Full Text] [Related]
11. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Takahashi M; Abe M
Br J Cancer Suppl; 1996 Jul; 27():S61-4. PubMed ID: 8763848
[TBL] [Abstract][Full Text] [Related]
12. Bioreductive drugs and the selective induction of tumour hypoxia.
Bremner JC; Stratford IJ; Bowler J; Adams GE
Br J Cancer; 1990 May; 61(5):717-21. PubMed ID: 2110814
[TBL] [Abstract][Full Text] [Related]
13. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model.
Hicks KO; Fleming Y; Siim BG; Koch CJ; Wilson WR
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):641-9. PubMed ID: 9806526
[TBL] [Abstract][Full Text] [Related]
14. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
Zhang M; Stevens G
Melanoma Res; 1998 Dec; 8(6):510-5. PubMed ID: 9918413
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
Monge A; Palop JA; López de Ceráin A; Senador V; Martínez-Crespo FJ; Sainz Y; Narro S; García E; de Miguel C; González M
J Med Chem; 1995 May; 38(10):1786-92. PubMed ID: 7752202
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
Fracasso PM; Sartorelli AC
Cancer Res; 1986 Aug; 46(8):3939-44. PubMed ID: 3089583
[TBL] [Abstract][Full Text] [Related]
17. The influence of hypoxia on the cytotoxicity of concomitant KW-2149 and ionizing irradiation in Chinese hamster fibroblasts.
Egelmeers A; Dirix LY; Lyczek J; De Bruijn EA; Van Oosterom AT; Scalliet P
Anticancer Drugs; 1996 Jul; 7(5):586-90. PubMed ID: 8862727
[TBL] [Abstract][Full Text] [Related]
18. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under acidic conditions.
Begleiter A; Leith MK
Mol Pharmacol; 1993 Jul; 44(1):210-5. PubMed ID: 8341273
[TBL] [Abstract][Full Text] [Related]
19. Over-expression of Bcl-2 protects against apoptosis induced by the bioreductive cytotoxic drug SR4233 (Tirapazamine).
Gilbert MS; Rupnow BA; Ramirez DA; Trisler KD; Knox SJ
Cell Death Differ; 1996 Apr; 3(2):215-22. PubMed ID: 17180085
[TBL] [Abstract][Full Text] [Related]
20. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake.
Skarsgard LD; Skwarchuk MW; Vinczan A; Kristl J; Chaplin DJ
Anticancer Res; 1995; 15(1):219-23. PubMed ID: 7733636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]